Clinical trial
Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)
NCT00242489 · Organon and Co, Industry · Completed
Key facts
| NCT number | NCT00242489 |
|---|---|
| Title | Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007) |
| Official title | A Placebo-Controlled, Parallel-Group, Double-Blind Study to Assess Safety and to Define the Clinically Effective Dose Range of MK0663 in Patients With Osteoarthritis of the Knee, Followed by a Double-Blind, Active-Comparator-Controlled Extension. |
| Lead sponsor | Organon and Co, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Osteoarthritis |
| Intervention type | Drug |
| Interventions | MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks), Placebo, Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks, Part II (Diclofenac) 8 weeks |
| Enrollment | 1,167 |
| Start date | Jun 1, 1998 |
| Primary completion | Feb 1, 1999 |
| Completion | Jul 1, 2002 |
| First posted | Oct 20, 2005 |
| Last update posted | Feb 18, 2022 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: